RadiSys Corporation (NASDAQ:RSYS)

RadiSys Corporation (NASDAQ:RSYS) Implodes As Loss Spooks Investors

RadiSys Corporation (NASDAQ:RSYS)

Shares of RadiSys Corporation (NASDAQ:RSYS) fell to a new 52-week low after the global leader in Open telecom solutions reported disappointing third quarter financial results. The stock fell 32.03% in Wednesday’s trading session to end the day at $0.87 a share.

RadiSys Corporation (NASDAQ:RSYS)

Radisys Q3 Financial Results

Investors pushed the stock lower on the company reporting a net loss of (-$15.4) million or (-$0.39) a share, more than double a net loss of (-$7.6) million reported last year. Gross margin in the quarter shrunk to 10.8% compared to 29.4% in the third quarter of 2016.

Concerned with the spiraling net loss, RadiSys Corporation (NASDAQ:RSYS) has implemented a revised go-to-market strategy that will allow it to refine its cost structure. Plans are also underway to advance the current funnel of prospective and existing customer opportunities.

RadiSys Corporation (NASDAQ:RSYS) has generated revenues of $11.3 million up from $10.4 million reported last year. However, it was a decline from $11.4 million reported in the second quarter. The company attributes the decline to timing of professional services programs whose impact will be felt in the fourth quarter

“Importantly, we made tangible progress in the third quarter towards converting proof-of-concepts into commercial wins as evidenced by the two new Media Engine VoLTE wins as well as our first commercial award for deployment of our new Flow Engine appliance, the TDE-200,” said Brian Bronson, Radisys President, and Chief Executive Officer.

For the fourth quarter, the company expects revenues of between $29 million and $33 million, helped by certain MediaEngine orders. Radisys also expects a net loss of between (-$0.19) and (-$0.13) a share.

RadiSys-Mavenir Partnership

Separately, RadiSys Corporation (NASDAQ:RSYS) and Mavenir have joined forces to enable Communications services providers commercially deploy Mobile Central Office Re-architected as a Datacenter (M-CORD). The open reference solution is designed to provide capabilities for unlocking innovation across open networking ecosystem with cloud economies.

Under the partnership, RadiSys Corporation (NASDAQ:RSYS) is to integrate Maveni’r’s carried grade vEPC into its M-CORD Distribution. The integration should accelerate CSPs path to network integration.

“We’re pleased to partner with Mavenir to advance CSPs’ ability to break vendor lock-in, accelerate service innovation and lower CapEx and OpEx through commercial deployment of the M-CORD architecture,” said Neeraj Patel, vice president and general manager, MobilityEngine, Radisys.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RSYS and receive breaking news on other hot stocks by signing up for our free newsletter!

Agenus Inc. (NASDAQ:AGEN) Unchanged As Q3 Earnings Meet Estimates

Agenus Inc. (NASDAQ:AGEN)

Shares of Agenus Inc. (NASDAQ:AGEN) traded higher, days after the company reported third quarter financial results that met consensus estimates. The stock was up by 0.29% in Thursday’s trading session to end the day at $3.51 a share.

Agenus Inc. (NASDAQ:AGEN)

AGEN Stock Performance

The stock is currently trading in a downtrend after struggling to close above $4.80. For the full year, the stock is down by more than 10%. Agenus Inc. (NASDAQ:AGEN) faces immediate support at $3.40, below which it could drop to a 52-week low of $3.20 a share.

Investor confidence has taken a hit in recent months. It now awaits to be seen if the third quarter financial results will help reinvigorate investor sentiments going forward. For the three months ended September 30, 2017, the immuno-oncology company reported a net loss of (-$36.8) million or (-$0.37) a share, compared to a net loss of (-$40.8) million reported last year.

Net Loss

For the first nine months of the year, Agenus Inc. (NASDAQ:AGEN) reported a net loss of (-$85.7) million compared to a net loss of (-$100.9) million or (-$1.16) a share reported last year. The decrease in net loss was due to the accelerated milestone payment received from Incyte.

Agenus used a total of $26.2 million in operating activities in the quarter, up from $23.8 million used for the corresponding period last year. Cash and cash equivalent as of the end of the quarter totaled $70.1 million compared to $76.4 million as of December, 31, 2016.

Pipeline Development

The developer of immune checkpoint antibodies and cancer vaccines also achieved significant milestones on the development of its pipeline of drugs.

“We are committed to continuing to innovate having generated several first-in-class and best-in-class immuno-oncology agents; our partnering discussions are maturing on multiple fronts and we expect to close on several business development transactions across our portfolio between now and the end of the first quarter of 2018,” said CEO, Garo Armen.

Agenus Inc. (NASDAQ:AGEN) plans to complete a Phase 1 dose-escalation and generate safety and pharmacodynamics data of AGEN1884 in the fourth quarter. It also plans to commence combination trials of AGEN 1884 and AGEN2034 before the end of the year.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AGEN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

OncoSec Medical Inc. (NASDAQ:ONCS

OncoSec Medical Inc. (NASDAQ:ONCS) Hits Record Highs after Trial Results

OncoSec Medical Inc. (NASDAQ:ONCS)

Shares of OncoSec Medical Inc. (NASDAQ:ONCS) hit a new record high after the company reported positive follow-up data from its Phase 2 OMS 1-102 combination study of ImmunoPulse IL-12 and Keytruda. The stock was up by 60% in Monday’s trading session to end the day at $2 a share.

OncoSec Medical Inc. (NASDAQ:ONCS

ONCS Stock Performance

OncoSec Medical Inc. (NASDAQ:ONCS) is currently trading in an uptrend, after being in consolidation for the better part of the year. For the full year, the stock is up by more than 60%. Following the rally, Maxim analyst Jason Kolbert has assigned a ‘Buy’ rating on the stock with a share price target of $5. The price target represents a 146% potential upside from current trading levels.

Renewed investor interest on the stock follows the announcement that a combination of ImmunoPulse il-12 and Keytruda demonstrated a 57% progression-free survival at 15 months.

Trial Results

According to OncoSec Medical Inc. (NASDAQ:ONCS), the new data demonstrates that a combination of the two therapies can prime a coordinated innate and adaptive immune response. The findings also suggest that the approach can reshape the tumor microenvironment yielding a robust anti-tumor response.

“The robust PFS benefit and tolerability observed with ImmunoPulse IL-12 plus pembrolizumab is the first demonstrating efficacy in a predicted PD-1 non-responder population and shows that the combination represents a potentially important addition to the treatment landscape for metastatic melanoma patients who have progressed or are progressing on anti-PD-1 therapy,” said CEO Dan O’Connor.

OncoSec Financial Results

Separately, OncoSec Medical Inc. (NASDAQ:ONCS) reported fourth-quarter financial results that indicated a significant improvement in operational efficiencies. For the three months ended July 31, 2017, the company generated a net loss of (-$5.8) million or (-$0.28) a share. The performance was an improvement from a net loss of (-$6.6) million reported last year.

OncoSec Medical Inc. (NASDAQ:ONCS) full-year net loss came in at (-$21.4) million or (-$1.06) a share, compared to a net loss of (-$26.9) million reported last year. The company attributes the decrease in net loss to a $2.2 million reduction in non-stock-based compensation. Research and development expenses also dropped from $14.7 million as of last year to $$12 million.

OncoSec Medical Inc. (NASDAQ:ONCS) exited the FY2017 with a total of $11.4 million in cash and cash equivalent compared to $28.7 million as of July 31, 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONCS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Otonomy Inc (NASDAQ:OTIC)

Lots of Good News out for Otonomy Inc (NASDAQ:OTIC)

Otonomy Inc (NASDAQ:OTIC)

Otonomy Inc (NASDAQ:OTIC) released their Q3 earnings after today’s market close and beat analyst expectations. Otonomy posted a net loss of (-$20.99) million, or (-$0.69) per share – versus the consensus forecast of a (-$0.76) EPS loss. Revenues for the quarter came in at $300,000.

Otonomy Inc (NASDAQ:OTIC)

San Diego, CA-based Otonomy Inc (NASDAQ:OTIC) is a biopharmaceutical company that develops and commercializes therapeutics for patients suffering from ear diseases and disorders. FDA-approved OTIPRIO® (ciprofloxacin otic suspension) is used during tympanostomy tube placement surgery in pediatric patients, an sNDA has been accepted for filing by the FDA for acute otitis externa (AOE) and a successful End-of-Phase 2 review has been completed with the FDA for acute otitis media with tympanostomy tubes (AOMT). OTIVIDEXTM is a steroid in development for the treatment of Ménière’s disease.

David A. Weber, Ph.D., president and CEO of Otonomy Inc (NASDAQ:OTIC) said “Today’s announcement of successful results for OTIVIDEX in the AVERTS-2 trial is an important milestone for the company and renews our excitement and commitment to continuing the registration program for OTIVIDEX in Ménière’s disease. We believe that the continuation of OTIVIDEX development for Ménière’s disease and the advancement of our other programs targeting important unmet medical needs including hearing loss and tinnitus provide an attractive path forward for Otonomy.”

Phase 3 Endpoints Met

Otonomy Inc (NASDAQ:OTIC) also announced today that the AVERTS-2 Phase 3 clinical trial of OTIVIDEX in patients with Ménière’s disease achieved its primary efficacy endpoint. The OTIVIDEX group demonstrated a 6.2 day reduction in the mean reported number of DVD from baseline to Month 3 with a 2.5 day mean difference between OTIVIDEX and placebo in Month 3. Otonomy plans to review these results with the U.S. Food and Drug Administration (FDA) and discuss clinical requirements for registration of OTIVIDEX for patients with Ménière’s disease. The company expects to provide an update from discussions with the FDA during the first quarter of 2018.

OTIC Stock Performance

Otonomy Inc (NASDAQ:OTIC) sales were first reported in 2016. That figure was $700,000. Earnings for 2016 were, on a per share basis, reported as a loss of (-$3.69). For the year prior, 2015, the EPS loss was (-$2.58).

The current closing price of $2.80 represents a large discount to the stock’s cash/share value of $4.97 as well as its book/share value of $4.96.

Four investment firms follow Otonomy Inc (NASDAQ:OTIC). Two rate OTIC stock as a “Strong Buy”, while the other two rate the shares as a “Hold”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OTIC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

pSivida Corp. (NASDAQ:PSDV)

pSivida Corp. (NASDAQ:PSDV) Gains as Earnings Meet Expectations

pSivida Corp. (NASDAQ:PSDV)

Shares of biotechnology company pSivida Corp. (NASDAQ:PSDV) gained 6% to end the trading day at $1.23 after the company reported a Q1 loss of (-$6) million or (-$0.15) per share on $385,000 in revenues. The results met Wall Street expectations, according to Zacks Investment Research.

pSivida Corp. (NASDAQ:PSDV)

The news release also revealed several operational events that could have an impact on PSDV prices in the future. The company met with the U.S. Food and Drug administration (FDA) on their plans to file a New Drug Application (NDA) for Durasert later this year or early next year. pSivida also entered into collaboration agreements with two global pharmaceutical companies to develop sustained-release glaucoma drugs. Lastly, the company changed the terms of a royalty payment agreement to be based on net sales.

pSivida Corp. (NASDAQ:PSDV), headquartered in Watertown, MA, develops sustained release drug products for treating eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases.

pSivida CEO Comments

Nancy Lurker, President & CEO of pSivida Corp. (NASDAQ:PSDV) commented “We continued to build our operating momentum during the fiscal first quarter. We signed two collaboration agreements with leading pharmaceutical companies that illustrate our ability to leverage our proven drug release technology to generate non-dilutive financing.   We have a number of milestones over the next few months, primarily the NDA filing for posterior segment uveitis, which we continue to expect to file in late December 2017 or early January 2018.  We await the data from the Phase 1 knee osteoarthritis (OA) trial and continue pre-clinical work on our shorter-duration Durasert.”

PSDV Stock Performance

In 2017, two investment firms initiated coverage on PSDV shares with a “Buy” rating. Their consensus, one-year price target is $6.50. However,

In August of 2017, PSDV stock hit its 52-week low of $1.03. Shares are around 50% off their 52-week high of $2.45 hit two months earlier, in June.

For the year, shares of pSivida Corp. (NASDAQ:PSDV) are down 44%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PSDV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Vical Incorporated (NASDAQ:VICL) Trading at a Discount?

Vical Incorporated (NASDAQ:VICL)

Vical Incorporated (NASDAQ:VICL) stock has rebounded off its 52-week low, established yesterday, but is giving up gains as the trading day progresses. Volume is over ten times the listed daily volume. Yesterday the biotechnology company closed at $1.66, a new 52-week low, then today the market gapped up and shares opened at $2.08 before hitting their inter-day high of $2.12. Since then, sellers have stepped in and VICL shares are trading under $1.90 as of this writing (12:25 PM EST).

Vical Incorporated (NASDAQ:VICL)

The rebound came after the company announced the pricing of its upcoming underwritten offering of 14,285,714 shares of common stock, or common stock equivalents, at $1.75 per share. The gross proceeds are expected to be approximately $25 million, before deducting expenses payable by Vical. The offering is expected to close on or about November 10, 2017. Vical has granted the underwriter a 30-day option to purchase up to an additional 2,142,857 shares of common stock in connection with the public offering.

San Diego, CA-based Vical Incorporated (NASDAQ:VICL) develops products using its proprietary DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It is developing various DNA-based vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 – currently in a Phase II clinical trial to prevent and protect against lesion recurrence. Vical has collaborations with Astellas to develop and commercialize therapies for the control and prevention of CMV infection in immunocompromised patients. The company has also collaborated with Merial for use of the Vical’s DNA delivery technology to design a therapeutic vaccine that helps extend the survival time of dogs with oral melanoma.

VICL Stock Performance

The lone investment firm that follows Vical Incorporated (NASDAQ:VICL), rates VICL stock as a “Strong Buy”. It has given VICL stock a one-year price target of $7.10.

EPS losses have been contracting since 2013 when the company posted a figure of (-$3.60). In 2016, that EPS loss was just (-$0.90). Those losses came on the back of erratic annual sales numbers. In 2012, Vical reported sales of $17.5 million, followed by, in 2013, $7.7 million, then $15.2 million, $21 million, then, for 2016, $14.5 million.

Interestingly, VICL stock is currently trading under its posted cash/share figure of $2.54 and its book/share value of $3.29.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $VICL and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Jaguar Health Inc. (NASDAQ:JAGX)

Jaguar Health Inc. (NASDAQ:JAGX) Program Receives Regulatory Approval

Jaguar Health Inc. (NASDAQ:JAGX)

Jaguar Health Inc. (NASDAQ:JAGX) traded lower after announcing the approval of its education program, ‘Diarrhea in Foals’ for veterinarians and Veterinary Technicians. Shares of the company fell 6.2% in Tuesday’s trading session to end the day at $0.161 a share.

Jaguar Health Inc. (NASDAQ:JAGX)

Diarrhea in Foals AAVSB Approval

The approval by The American Association of Veterinary State Boards (AAVSB) allows the company to offer 1.50 CE credits to each participating veterinarian or veterinary technician.

“Participation in CE programs helps veterinarians and veterinary technicians remain apprised of current and cutting-edge veterinary care. Helping veterinary professionals expand their clinical knowledge and learn about new technology helps them take better care of their patients,” said equine medical consultant Dr. Siobhan McAuliffe, MVB, DACVIM.

Tuesday’s sell-off capped yet another poor run as the stock continues to register lower lows in the market. The stock has lost more than 70% in market value since the start of the year. Jaguar Health is currently trading in a downtrend and close to its 52-week low of $0.18 a share.

Mytesi Commercialization

Jaguar Health Inc. (NASDAQ:JAGX) is a natural-products pharmaceuticals company focused on developing and commercializing novel gastrointestinal products for human and animal use. The company’s wholly-owned subsidiary develops and commercializes these products for the global marketplace. Mytesi is the company’s lead, FDA-approved product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS.

Jaguar Health Inc. (NASDAQ:JAGX) subsidiary has launched a ‘Keep your pants on’ campaign as it seeks to raise awareness and engage with people living with HIV and Aids. The campaign seeks to provide an easy way of discussing embarrassing topics such as HIV related diarrhea.

Separately Jaguar Health carried out an underwritten public offering of 21.3 million shares of voting common stock in September. The company expects gross proceeds of $4.25 million after pricing the offering at $0.20 a share.

Jaguar Health Inc. (NASDAQ:JAGX) plans to use net proceeds from the offering for commercialization of its lead product Mytesi and for general corporate purposes as well as working capital.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $JAGX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Genocea Biosciences Inc. (NASDAQ:GNCA)

Investor Confidence in Genocea Biosciences Inc. (NASDAQ:GNCA) Drops

Genocea Biosciences Inc. (NASDAQ:GNCA)

Investor confidence in Genocea Biosciences Inc. (NASDAQ:GNCA) has taken a hit in the wake of disappointing third quarter financial results. Shares of the company fell 12.6% in Tuesday’s trading session as law firms alleged possible securities violations following the earnings report.

Genocea Biosciences Inc. (NASDAQ:GNCA)

Class Action Investigation

A wider than expected net loss for the quarter appears to have spooked investors, accelerating a sell-off that began in May. The stock has shed more than 70% of its total market value since the start of the year as it continues to trade in a strong downtrend.

The stock’s sentiments have also taken a hit from law firms that allege the company provided materially false and misleading statements regarding business operation and compliance policies. According to Pomerantz LLP, the biopharmaceutical company failed to disclose its funds were insufficient to support Phase 3 trials of GEN-03.

Genocea Biosciences Inc. (NASDAQ:GNCA) is also accused of overstating the potential of its lead candidate drug GEN-003. In September, the company was forced to halt spending and development activities of the drug as it explored strategic alternatives. The news caused the stock to drop 76.5% to close at $1.25 a share.

Q3 Financial Results

In addition to the class action lawsuit, a Q3 net loss of (-$16.9) million compared to a net loss of (-$12.8) million reported last year has not gone well with investors. Research and development expenses in the quarter increased $1.3 million to $1.2 million. The company attributes the increase to higher external manufacturing related expenses and increase in compensation to support Phase development of GEN-003.

During the third quarter, Genocea Biosciences Inc. (NASDAQ:GNCA) implemented a corporate restructuring that resulted in a strategic shift to immuno-oncology. The changes resulted in a charge of $1.1 million to be paid in the fourth quarter. The company exited the quarter with cash and cash equivalent of $22 million compared to $35.2 million at the end of the second quarter. The existing finances are sufficient to support operating expenses and capital expenditure into the middle of 2018.

Separately, Genocea Biosciences Inc. (NASDAQ:GNCA) is to highlight the power of its proprietary antigen identification system ATLAS at the upcoming Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

“These data demonstrate the versatility of ATLAS and support our use of the technology in the development of next-generation neoantigen cancer vaccines,” said Jessica Baker Flechtner, Ph.D., chief scientific officer at Genocea.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $GNCA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Argos Therapeutics Inc. (NASDAQ:ARGS)

Argos Therapeutics Inc. (NASDAQ:ARGS) Balance Sheet Receives $1.5 Million

Argos Therapeutics Inc. (NASDAQ:ARGS)

Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) fell 8.76% after the immuno-oncology company announced a receipt of $1.5 million milestone payment from Lummy Co Ltd. The payment pertains to a technology transfer for the manufacturing of Rocapuldencel-T.

Argos Therapeutics Inc. (NASDAQ:ARGS)

Argos 90% Drop

Rocapuldencel-T is the company’s most advanced product candidate, currently in Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma.

“We appreciate Lummy’s continued commitment to Argos and the Rocapuldencel-T development program,” stated Jeff Abbey, CEO of Argos. “Given the complexity of the manufacturing process for Rocapuldencel-T, we were pleased to complete this important milestone in our alliance.

Argos Therapeutics Inc. (NASDAQ:ARGS) remains subdued after feeling the full effect of selling pressure since the start of the year. The stock has shed more than 90% of its total market value this year, as it continues to trade in a strong downtrend. It faces immediate support at $0.14, below which it could drop to its 52-week low of $0.14.

Argos Therapeutics Inc. (NASDAQ:ARGS) will announce its third quarter financial results for the three months ended September 30, 2017, on November 9, 2017. The financial results could have an impact on the direction of trade of the stock, depending on its outcome.

Argos Pipeline

The immuno-oncology company is to provide an update on ongoing Phase 3 ADAPT clinical trial evaluating the use of Rocapuldencel-T for the treatment of metastatic renal cell carcinoma. Argos Therapeutics enrolled a total of 462 patients into the trial.

In addition to Rocapuldencel-T, Argos Therapeutics Inc. (NASDAQ:ARGS) is also developing a separate Arcelis-based product candidate AGS-004 for the treatment of human immunodeficiency virus. The candidate drug is currently being evaluated in combination with vorinostat, a latency reversing drug. The Nation Institute of Health has provided a portion of the funding for the candidate drug’s development.

Separately, Argos Therapeutics Inc. (NASDAQ:ARGS) has appointed Richard Morrison to its board of directors. He will serve as a Class III director and in the audit committee. Morrison joins the company with vast experience in the pharmaceutical and finance industry.

“Dick has considerable pharmaceutical industry and financial expertise, and we look forward to the benefit of his experience as we seek to advance our novel pipeline of individualized immunotherapies directed at important diseases, including metastatic renal cell carcinoma and HIV,” said Chairman, Hubert Birner.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ARGS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

New Lows for Curis, Inc. (NASDAQ:CRIS)

Curis, Inc. (NASDAQ:CRIS)

Shares of Curis, Inc. (NASDAQ:CRIS) are down 17.5% after the biotechnology company reported a (-$15.5) million, or (-$0.11) per share, loss on $2.4 million in revenue for Q3 2017. The company’s results were below analyst expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of (-$0.09) cents per share. For the same period last year, Curis reported a net loss of (-$28.3) million, or (-$0.21) per share.

Curis, Inc. (NASDAQ:CRIS)

Curis, Inc. (NASDAQ:CRIS) is a biotechnology company that develops and commercializes drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis also collaborates with Aurigene in the areas of immuno-oncology and precision oncology. Curis is also in collaboration with biotechnology giant Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.

CRIS Stock Performance

Shares of Curis, Inc. (NASDAQ:CRIS) hit new 52-week lows, $1.23, after the earnings announcement was released. The 52-week high was established back in November of 2016. However, shares have taken a beating since then and lost over 40% of their value. Year-to-date, CRIS stock performs even worse – down over 50%.

All four investments firms that follow Curis, Inc. (NASDAQ:CRIS) rate CRIS shares as a “Strong Buy” and have a consensus price target of $5.50. This is noteworthy as sales have been in decline for the past five years. In 2012, the company posted sales of $17 million. That figure shrank every year and for 2016 sales were posted at just $7.5 million. On top of the poor sales performance, CRIS shares have had negative earnings for the past five years with the two largest losses coming in 2015 (-$0.48) and 2016 (-$0.46).

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CRIS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.